Division of Genetics and Cell Biology, Genomic Unit for the Diagnosis of Human Pathologies, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy.
Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy.
Cancer Biomark. 2018;22(2):351-357. doi: 10.3233/CBM-181218.
Sensitive and specific biomarkers of Pancreatic Ductal Adenocarcinoma (PDAC) are desperately needed to allow early diagnosis and improve patient's survival. Ezrin autoantibodies were recently described as present in 93% of PDAC patients and 40% of healthy subjects who later developed PDAC. However, another prospective study failed to replicate these findings. Both studies were based on the use of a solid phase ELISA immunoassay.
We aimed at re-evaluating the usefulness of Ezrin autoantibodies as PDAC biomarkers using the Luciferase Immuno Precipitation System (LIPS), an alternative immunoassay format that found successful application for the measurement of autoantibodies against pancreatic autoantigens.
We produced a Nanoluciferase™ tagged Ezrin (NLuc-Ezrin). NLuc-Ezrin was then used as antigen in LIPS to test for Ezrin autoantibodies patients affected by PDAC (n= 40), other pancreatic diseases (OPD, n= 50), and healthy controls (n= 60).
Overall, binding in liquid phase to Ezrin by serum antibodies was rare and low titer. Furthermore, we did not find statistically significant differences in the prevalence of Ezrin autoantibodies between patients affected by either PDAC or OPD compared to control.
Our results do not confirm the usefulness of Ezrin autoAbs as biomarker of PDAC.
迫切需要灵敏和特异的胰腺导管腺癌（PDAC）生物标志物，以实现早期诊断并提高患者的生存率。Ezrin 自身抗体最近被描述为 93%的 PDAC 患者和 40%后来发展为 PDAC 的健康受试者存在。然而，另一项前瞻性研究未能复制这些发现。这两项研究均基于固相 ELISA 免疫测定法。
我们旨在使用 Luciferase Immuno Precipitation System（LIPS）重新评估 Ezrin 自身抗体作为 PDAC 生物标志物的有用性，LIPS 是一种替代免疫测定格式，已成功应用于测量针对胰腺自身抗原的自身抗体。
我们生产了一个 Nanoluciferase™标记的 Ezrin（NLuc-Ezrin）。然后，NLuc-Ezrin 被用作 LIPS 中的抗原，以测试受 PDAC（n=40）、其他胰腺疾病（OPD，n=50）和健康对照（n=60）影响的患者的 Ezrin 自身抗体。
总的来说，血清抗体与 Ezrin 在液相中的结合很少且滴度较低。此外，我们没有发现 PDAC 或 OPD 患者与对照组之间 Ezrin 自身抗体的患病率存在统计学上的显著差异。
我们的结果不确认 Ezrin 自身抗体作为 PDAC 生物标志物的有用性。
